Building a Vonoprazan PCD Franchise Business: A Practical Roadmap for Tier-2 and Tier-3 India
Plenty of articles explain why Vonoprazan is a hot molecule right now. Fewer explain what a franchise partner should actually do with that opportunity once they've decided to pursue it. Knowing that the gastro segment is growing doesn't tell you which territory to pick, how to structure your first six months with prescribing doctors, or when to expect the business to actually turn a profit. This piece is the practical follow-up: a working roadmap for building a Vonoprazan PCD franchise business , with a real precedent from Indian pharma history worth studying before you start. The Precedent Worth Studying: How Eris Lifesciences Built a Chronic-Therapy Business in Smaller Cities Before picking a territory or a product line, it's worth understanding how this playbook has already worked in India. Eris Lifesciences started in 2007 with a deliberate focus on chronic therapy segments — cardiovascular, anti-diabetic, and thyroid — and built early, deep relationships with specia...